Catalyst Wire Dossier Catalyst Wire Dossier

Emtricitabine/tenofovir alafenamide (F/TAF)

emtricitabine/tenofovir alafenamide · Gilead Sciences
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Emtricitabine/tenofovir alafenamide (F/TAF), covering 2020-03-17 to 2020-03-17. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection [Phase 3]

See pricing